We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

BIO-RAD LABORATORIES

  Gold Provides full range of instrumentation, reagent kits, software and quality control systems to clinical laboratories. ... read more Featured Products: More products

Download Mobile App




Events

ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
24 Jan 2022 - 27 Jan 2022

Point-of-Care Device Accurately Rapidly Diagnoses Sickle Cell Disease

By LabMedica International staff writers
Posted on 25 Nov 2021
Print article
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)
Image: The Gazelle Hb Variant Test for screening, diagnosis and management of sickle cell disease and related hemoglobinopathies at the point of care (Photo courtesy of Hemex Health)
Hemoglobinopathies are the most common autosomal hereditary disorders. Approximately 7% of the global population carries hemoglobin gene mutation including structural hemoglobin variants like sickle hemoglobin or thalassemia.

Sickle cell disease is a major public health problem in India. Lack of rapid and reliable diagnostic methods result in many avoidable deaths in affected population. Current diagnostic tools are laboratory based, expensive and need trained manpower. Early diagnosis is crucial to initiating life-saving therapies and knowledge of sickle cell carrier status is critical to prevention and parental planning for at-risk populations.

Medical Scientists at the ICMR-National Institute of Research in Tribal Health (Jabalpur, India) screened a total of 1,050 patients by sickle cell solubility, hemoglobin (cellulose acetate) electrophoresis, high-performance liquid chromatography (HPLC) and the Gazelle point-of-care device. Sickle positive samples were also confirmed by HPLC using Beta-thalassemia (betathal) short program (VARIANT II, Bio-Rad Laboratories, Inc., Hercules, CA, USA). HPLC and standard cellulose acetate electrophoresis were considered to be the reference standard for comparisons.

Gazelle (Hemex Health, Portland, OR, USA) is a single-use cartridge-based test that enables rapid, affordable, quantitative, accurate diagnosis for both sickle cell anemia (SCA) and carrier status at the point of care. It is a cellulose acetate-based microchip electrophoresis system within a portable instrument, utilizing the principle of standard electrophoresis method with inbuilt analysis software, electronic data storage, and wireless data transmission capabilities. The test provides actionable quantitative hemoglobin information from a finger stick blood sample during the patient visit in less than 10 minutes.

The investigators reported that of the total 1,027 test results obtained, 960 tests were “Valid” (93.5%) and included in the analysis. Gazelle identified all patients with disease (HbSS and Thalassemia Major) with 100% accuracy. Gazelle demonstrated 100% sensitivity when comparing sickle cell disease (SCD) versus sickle cell trait and SCD versus normal. Specificity was 98.9% and 99.5% when comparing SCD versus trait and trait versus normal, respectively. Specificity was 99.8% when comparing SCD versus normal and sensitivity was 99.3% when comparing trait versus normal. Overall, Gazelle yielded a high accuracy (99.0%) compared to reference standard tests (hemoglobin electrophoresis and HPLC).

The authors concluded that Gazelle is a low-cost, rapid diagnostic test with high accuracy for detecting SCD both quantitatively and qualitatively. Gazelle can be a potential screening tool for the rapid diagnosis in resource limited settings and developing countries with high burden of hemoglobin disorders. The study was published on October 13, 2021 in the journal Frontiers in Medicine.

Related Links:
ICMR-National Institute of Research in Tribal Health
Bio-Rad Laboratories
Hemex Health


Gold Supplier
BMP Whole Blood Analyzer
GEM Premier ChemSTAT
New
Gold Supplier
SARS-CoV-2 (ORF1a, N, RdRp) Real-Time RT-PCR Test
DiaPlexQ SARS-CoV-2 (ORF1a, N, RdRp)
New
Live Cell Analysis System
BioTek BioSpa
New
Automated Nucleic Acid Extraction System
MAGNETITE

Print article
IIR Middle East

Channels

Molecular Diagnostics

view channel
Illustration

Point-of-Care Lateral Flow Test Detects Bladder Cancer Using Urine Sample within Minutes

A breakthrough diagnostics platform uses a multiplexed lateral flow assay that detects 10 bladder cancer biomarkers from a urine sample in either laboratory or point-of-care settings. SCIENION (Berlin,... Read more

Industry

view channel
Illustration

Global Immunofluorescence Assay (IFA) Market to Surpass USD 4 Billion by 2028 Due to Growing Burden of Infectious Diseases

The global immunofluorescence assay (IFA) market is expected to reach USD 4.01 billion by 2028, driven by the increasing global healthcare burden of chronic and infectious diseases, rising application... Read more
Copyright © 2000-2022 Globetech Media. All rights reserved.